Ovarian cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BRCA1 20
• BRCA2 13
• PARP 27
• TP53 6
• PD-1 12
• AKT 2
• HER2 16
• PD-L1 7
• PI3K 3
• STAT3 1
• mTOR 0
• VEGF 6
• KRAS 6
• EGFR 3
• PTEN 2
• CTNNB1 0
• FAK 1
• MAPK 0
• MYC 0
• NRF2 0
• CTLA-4 6
• ERK 1
• JAK 0
• STING 0
• GPX4 0
• HIF-1 0
• MEK 1
• TROP2 4
• PALB2 5
• B7-H3 7
• CDK4/6 4
• ATM 1
• CD47 0
• IL-6 0
• PIK3CA 3
• EZH2 1
• JNK 0
• YAP 0
• BCL-2 0
• BRAF 4
• CXCR4 0
• HDAC 0
• PPAR 0
• AMPK 0
• ARID1A 3
• AXL 1
• COX-2 2
• NMDA 0
• TIGIT 0
• AR 0
• CD40 1
• HER3 1
• HMGB1 0
• KEAP1 1
• METTL3 0
• RAS 0
• TLR4 0
• FGFR 0
• PINK1 0
• PKM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 2,388 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

  NCT04840589· National Cancer Institute (NCI)· Updated 12 Nov 2026

  “Other - Pending amendment.”Registry text, quoted unchanged. Source

• Terminated

  Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

  NCT05075993· M.D. Anderson Cancer Center· Updated 10 Nov 2026

  “\<75% participation”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

  NCT07030907· Outpace Bio, Inc.· Updated 9 Nov 2026

  “Business decision”Registry text, quoted unchanged. Source

• Terminated

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Updated 5 Nov 2026

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Terminated

  AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

  NCT05617755· Arsenal Biosciences, Inc.· Updated 29 Oct 2026

  “Active patients have been rolled over to a separate LTFU study.”Registry text, quoted unchanged. Source

• Terminated

  huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

  NCT05057715· University of Pennsylvania· Updated 29 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  PRO1107 in Patients With Advanced Solid Tumors

  NCT06171789· Genmab· Updated 29 Oct 2026

  “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”Registry text, quoted unchanged. Source

• Withdrawn

  A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

  NCT05479045· Georgetown University· Updated 9 Oct 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Terminated

  Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer

  NCT05833321· Centre Hospitalier Metropole Savoie· Updated 8 Oct 2026

  “recruitement failure”Registry text, quoted unchanged. Source

• Suspended

  Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

  NCT05866679· M.D. Anderson Cancer Center· Updated 6 Oct 2026

  “Suspension”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  NCT01950572· National Cancer Institute (NCI)· Source

• Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

  NCT04585958· National Cancer Institute (NCI)· Source

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  NCT05564377· National Cancer Institute (NCI)· Source

• Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

  NCT05950464· National Cancer Institute (NCI)· Source

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  NCT01174121· National Cancer Institute (NCI)· Source

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Source

• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

  NCT04847063· National Cancer Institute (NCI)· Source

• Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

  NCT05554328· National Cancer Institute (NCI)· Source

• Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

  NCT04840589· National Cancer Institute (NCI)· Source

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 48
• Organoids 19
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 15
• Gene Expression Profiling 126
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 6
• Exome Sequencing 11
• Proteomics 62
• Metabolomics 17
• Mass Spectrometry 6
• Flow Cytometry 26
• Immunohistochemistry 95
• Liquid Biopsy 15
• Circulating Tumor DNA 13
• Xenograft Model Antitumor Assays 234
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 57
• Machine Learning 60
• Deep Learning 36
• Cohort Studies 105
• Genome-Wide Association Study 26

See which targets of this disease your abstract mentions, and go to the people working on them.